FindTrial
Sign In

Application of a novel molecular probe 99mTc-FAPI SPECT/CT in the early diagnosis, treatment monitoring and prognosis of fibrotic interstitial lung disease

Application of a novel molecular probe 99mTc-FAPI SPECT/CT in the early diagnosis, treatment monitoring and prognosis of fibrotic interstitial lung disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093808
Enrollment
Unknown
Registered
2024-12-12
Start date
2024-12-13
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial lung disease

Interventions

case series:None

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >=18 years old; (2) Patients diagnosed with fibrotic interstitial lung disease.

Exclusion criteria

Exclusion criteria: (1) Subjects who cannot be followed up according to the trial protocol; (2) Pregnant women.

Design outcomes

Primary

MeasureTime frame
99mTc-FAPI SPECT/CT imaging data;Forced vital capacity;diffusion lung carbon monoxide;—

Countries

China

Contacts

Public ContactBaosong Xie; Xiujuan Yao

Fujian Provincial Hospital

baosongx@fjmu.edu.cn+86 591 8821 7531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026